Ben K. Seon

3.2k total citations
100 papers, 2.6k citations indexed

About

Ben K. Seon is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Ben K. Seon has authored 100 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Molecular Biology, 39 papers in Radiology, Nuclear Medicine and Imaging and 32 papers in Immunology. Recurrent topics in Ben K. Seon's work include Monoclonal and Polyclonal Antibodies Research (37 papers), Glycosylation and Glycoproteins Research (21 papers) and Angiogenesis and VEGF in Cancer (19 papers). Ben K. Seon is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (37 papers), Glycosylation and Glycoproteins Research (21 papers) and Angiogenesis and VEGF in Cancer (19 papers). Ben K. Seon collaborates with scholars based in United States, United Kingdom and Japan. Ben K. Seon's co-authors include Yuro Haruta, Fumihiko Matsuno, David Pressman, Maurice Barcos, A.A. Sandberg, Hilda Tsai, Seiichi Matsui, Masao Kondo, Akinao Haba and Shigeru Negoro and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ben K. Seon

98 papers receiving 2.4k citations

Peers

Countries citing papers authored by Ben K. Seon

Since Specialization

Citations

This map shows the geographic impact of Ben K. Seon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben K. Seon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben K. Seon more than expected).

Fields of papers citing papers by Ben K. Seon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben K. Seon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben K. Seon. The network helps show where Ben K. Seon may publish in the future.

Co-authorship network of co-authors of Ben K. Seon

This figure shows the co-authorship network connecting the top 25 collaborators of Ben K. Seon. A scholar is included among the top collaborators of Ben K. Seon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben K. Seon. Ben K. Seon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b 2024 ·Leukemia Research ·Ben K. Seon, Morihiro Okazaki, (unknown), Fumihiko Matsuno, Andrew K.L. Goey, Orla Maguire	2
2	Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial 2023 ·SHILAP Revista de lepidopterología ·Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert B. Newton, Ahmad Ozair, Atulya Aman Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer	10
3	TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC) 2016 ·Annals of Oncology ·Toni K. Choueiri, Neeraj Agarwal, Thai H. Ho, Sumanta K. Pal, Ben K. Seon, (unknown), (unknown), Ronald Shazer, Charles P. Theuer	3
4	A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC) 2016 ·Annals of Oncology ·Toni K. Choueiri, M. Dror Michaelson, Edwin M. Posadas, Guru Sonpavde, David F. McDermott, Ben K. Seon, (unknown), Ronald Shazer, (unknown), Charles P. Theuer	5
5	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma 2016 ·Clinical Genitourinary Cancer ·Andrea B. Apolo, Fatima Karzai, Jane B. Trepel, Sylvia V. Alarcon, Sunmin Lee, Min-Jung Lee, Yusuke Tomita, Liang Cao, Yunkai Yu, Maria J. Merino, Ravi A. Madan, Howard L. Parnes, Seth M. Steinberg, (unknown), Ben K. Seon, James L. Gulley, Philip M. Arlen, Nancy A. Dawson, William D. Figg, William L. Dahut	37
6	A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·(unknown), Michael S. Gordon, Herbert I. Hurwitz, Роберто Пили, David S. Mendelson, (unknown), Delia Alvarez, Ben K. Seon, Charles P. Theuer, (unknown), Lee S. Rosen	1
7	Endoglin-Targeted Cancer Therapy 2010 ·Current Drug Delivery ·Ben K. Seon, Akinao Haba, Fumihiko Matsuno, Norihiko Takahashi, Masanori Tsujie, Xinwei She, Naoko Harada, Shima Uneda, Tomoko Tsujie, Hirofumi Toi, Hilda Tsai, Yuro Haruta	110
8	Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature 2009 ·International Journal of Cancer ·Shima Uneda, Hirofumi Toi, Tomoko Tsujie, Masanori Tsujie, Naoko Harada, Hilda Tsai, Ben K. Seon	54
9	Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice 2008 ·International Journal of Cancer ·Masanori Tsujie, Tomoko Tsujie, Hirofumi Toi, Shima Uneda, (unknown), Hilda Tsai, Ben K. Seon	46
10	Differential expression of endoglin (CD105) between human malignant epithelial tissues and cultured epithelial cell lines 2007 ·Cancer Research ·Tomoko Tsujie, Masanori Tsujie, Yuro Haruta, Maurice Barcos, Betsy O. Spaulding, Hilda Tsai, Ben K. Seon	1
11	Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin 2005 ·Cancer Immunology Immunotherapy ·(unknown), Naoko Harada, William R. Greco, Akinao Haba, Shima Uneda, Hilda Tsai, Ben K. Seon	28
12	Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells 2003 ·International Journal of Cancer ·Xinwei She, Fumihiko Matsuno, Naoko Harada, Hilda Tsai, Ben K. Seon	53
13	Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis 2003 ·British Journal of Cancer ·Chao Li, (unknown), Ben K. Seon, Sarah Duff, (unknown), Andrew G. Renehan, Sarah O’Dwyer, N. Haboubi, S. Kumar	102
14	Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8(CD79b) 1997 ·American Journal of Clinical Pathology ·E Moreau, Estella Matutes, Roger A’Hern, Alison Morilla, Ricardo Morilla, K Owusu-Ankomah, Ben K. Seon, Daniel Catovsky	257
15	Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. 1997 ·PubMed ·Ben K. Seon, Fumihiko Matsuno, Yuro Haruta, Masao Kondo, Maurice Barcos	137
16	Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex 1994 ·Molecular Immunology ·Stefan Vasile, J E Coligan, (unknown), Ben K. Seon	18
17	Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. 1994 ·PubMed ·(unknown), M. Yoshida, M. Okazaki, Sandra J. Yokota, Maurice Barcos, Ben K. Seon	25
18	Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and scid mice 1993 ·Leukemia Research ·(unknown), Tin Han, (unknown), Heinz‐Ulrich G. Weier, Morihiro Okazaki, Soichiro Yokota, (unknown), Xiao Han, (unknown), Maurice Barcos, Edward S. Henderson, Minoru Yoshida, Ben K. Seon	19
19	Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins. 1990 ·The Journal of Immunology ·Yi Luo, Ben K. Seon	9
20	Retinol-binding protein in the urine of cancer patients. 1979 ·PubMed ·Ben K. Seon, David Pressman	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact